RxDoctor Payments Data

Amber Powell

Family · Rocky Mount, NCNPI 1699446401

Payments from drug & device makers

$448in general payments, 2019–2025

Across 19 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$113
  • Novo Nordisk$105
  • AbbVie$61
  • Lilly USA, LLC$57
  • Exact Sciences$50
  • Ultragenyx Pharmaceutical Inc.$24
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$42996%
  • Education$184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$448 in reported general payments places this provider in the 55th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$15,720
Medicare patients
99
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin19$25,615
OzempicSemaglutide16$22,101
Aimovig AutoinjectorErenumab-Aooe15$11,571
EliquisApixaban11$8,147
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,482
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,451
Albuterol Sulfate HfaAlbuterol Sulfate42$1,096
Ventolin HfaAlbuterol Sulfate16$1,053
Atorvastatin Calcium64$898
Amlodipine Besylate72$677
Omeprazole31$624
Gabapentin46$590
Losartan Potassium71$574
Spironolactone-HctzSpironolact/Hydrochlorothiazid12$369
Levothyroxine Sodium43$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$105$22,10116 claims
PfizerEliquis$19$8,14711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,522 family providers in North Carolina.

Other family in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →